2025 Outlook: Biopharma Global Transaction Insights, Trends & Analysis
January 12, 2025
This report provides an in-depth analysis of the biopharma industry's transformative journey in 2024 and its trajectory into 2025. Key trends include the rapid evolution of R&D capabilities for next-generation modalities and the rising global influence of Chinese biopharma innovation. Notable therapeutic advancements, such as GLP-1 targeted obesity therapies and CNS breakthroughs, underscore the industry's focus on addressing challenging indications.
Strategic investments in emerging modalities like radiopharmaceuticals and bispecific antibodies, coupled with a competitive global M&A landscape, highlight the sector's adaptability amid shifting market dynamics. Additionally, regulatory alignment between the FDA and NMPA has streamlined global drug approvals, enhancing cross-border collaboration. With 43 in-licensing and 87 out-licensing deals in 2024, this report captures the critical drivers and partnerships shaping the future of biopharma innovation.
